KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBT: 2009-2024

Historic EBT for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $541.8 million.

  • Biomarin Pharmaceutical's EBT fell 119.58% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.3 million, marking a year-over-year increase of 73.53%. This contributed to the annual value of $541.8 million for FY2024, which is 187.31% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported EBT of $541.8 million as of FY2024, which was up 187.31% from $188.6 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's EBT ranged from a high of $541.8 million in FY2024 and a low of -$75.3 million during FY2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median EBT value was $188.6 million (recorded in 2023), while the average stood at $293.3 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's EBT plummeted by 53.78% in 2021 and then soared by 298.51% in 2022.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's EBT stood at -$49.0 million in 2020, then crashed by 53.78% to -$75.3 million in 2021, then spiked by 298.51% to $149.6 million in 2022, then rose by 26.07% to $188.6 million in 2023, then spiked by 187.31% to $541.8 million in 2024.